EYEN vs. CASI, VYNE, GANX, UNCY, HCWB, OCUP, XLO, NXTC, LEXX, and CARA
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), Gain Therapeutics (GANX), Unicycive Therapeutics (UNCY), HCW Biologics (HCWB), Ocuphire Pharma (OCUP), Xilio Therapeutics (XLO), NextCure (NXTC), Lexaria Bioscience (LEXX), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
25.8% of Eyenovia shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 7.1% of Eyenovia shares are owned by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, CASI Pharmaceuticals had 5 more articles in the media than Eyenovia. MarketBeat recorded 17 mentions for CASI Pharmaceuticals and 12 mentions for Eyenovia. Eyenovia's average media sentiment score of 0.16 beat CASI Pharmaceuticals' score of -0.28 indicating that Eyenovia is being referred to more favorably in the media.
CASI Pharmaceuticals received 30 more outperform votes than Eyenovia when rated by MarketBeat users. However, 65.13% of users gave Eyenovia an outperform vote while only 51.55% of users gave CASI Pharmaceuticals an outperform vote.
Eyenovia has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -105.76%. CASI Pharmaceuticals' return on equity of -97.58% beat Eyenovia's return on equity.
Eyenovia has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.
CASI Pharmaceuticals has higher revenue and earnings than Eyenovia. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
Eyenovia currently has a consensus target price of $10.00, indicating a potential upside of 1,233.51%. CASI Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 81.82%. Given Eyenovia's higher possible upside, equities research analysts clearly believe Eyenovia is more favorable than CASI Pharmaceuticals.
Summary
Eyenovia beats CASI Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
